The proportion of positive samples prior to C&D was lower in fattening than in other phases. The proportion of positive samples prior to and after C&D was 121/240 (50%) and 46/240 (19%) respectively. In the mixed effects PS-095760 logistic regression analysis it was shown not only that both productive phase and C&D were associated with the probability of having a positive sample but also that the C&D effect was different in the different productive phases. In particular the effect of C&D was stronger in farrowing crates than in the other productive
phases. The results of this study show that, although current practices of cleaning and disinfection reduce MRSA environmental contamination, they are likely to be inadequate to the elimination of the microorganism. However, a strict application of hygienic protocols can lead to a marked reduction of MRSA environmental contamination. (C) 2012
Elsevier Ltd. All rights reserved.”
“Contrast medium (CM)- induced nephropathy (CIN), defined as acute renal failure after administration of CM when alternative causes of renal damage have been excluded, is the third leading cause of acute renal injury necessitating hospitalization. selleck compound However, the pathophysiology of CIN is complex and not fully understood. Gadolinium chelates, originally introduced as intravenous CM for magnetic resonance imaging and regarded as nonnephrotoxic, have been recommended to replace iodinated contrast agents in patients at risk for acute renal failure. Since then, some
gadolinium-based CM have been reported to be associated with CIN, especially in patients with advanced renal disease. However, the biochemical and physicochemical properties of the gadolinium-chelates that are responsible for such nephrotoxicity have not Z-IETD-FMK order been clearly defined, and the issue of gadolinium-induced nephrotoxicity remains controversial. This review surveys the literature with the purpose of clarifying the renal effects of gadolinium-based CM in patients with renal insufficiency. (c) RSNA, 2009″
“Combined therapy of rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin (R-ESHAP) has been one of the most frequently used salvage regimens for relapsed/refractory non-Hodgkin’s lymphoma. In 2002, we introduced the modified R-ESHAP regimen in which cisplatin was switched to carboplatin. We evaluated the safety and effectiveness of this modified regimen by reviewing the records of 35 patients who had been administered R-ESHAP. Our cohort included 21 patients with diffuse large B cell lymphoma (DLBCL) and 14 patients with follicular lymphoma (FL). The overall response rate (ORR) was 48% for DLBCL and 93% for FL. The overall survival (OS) for patients with DLBCL was 51% with a median follow-up of 11 months, and 91% for patients with FL with a median follow-up of 36 months.